These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 32116540)
1. Laminin and Integrin in LAMA2-Related Congenital Muscular Dystrophy: From Disease to Therapeutics. Barraza-Flores P; Bates CR; Oliveira-Santos A; Burkin DJ Front Mol Neurosci; 2020; 13():1. PubMed ID: 32116540 [TBL] [Abstract][Full Text] [Related]
2. Secondary reduction of alpha7B integrin in laminin alpha2 deficient congenital muscular dystrophy supports an additional transmembrane link in skeletal muscle. Cohn RD; Mayer U; Saher G; Herrmann R; van der Flier A; Sonnenberg A; Sorokin L; Voit T J Neurol Sci; 1999 Mar; 163(2):140-52. PubMed ID: 10371075 [TBL] [Abstract][Full Text] [Related]
3. Current understanding and treatment of cardiac and skeletal muscle pathology in laminin-α2 chain-deficient congenital muscular dystrophy. Nguyen Q; Lim KRQ; Yokota T Appl Clin Genet; 2019; 12():113-130. PubMed ID: 31308722 [TBL] [Abstract][Full Text] [Related]
4. Human laminin-111 and laminin-211 protein therapy prevents muscle disease progression in an immunodeficient mouse model of LAMA2-CMD. Barraza-Flores P; Hermann HJ; Bates CR; Allen TG; Grunert TT; Burkin DJ Skelet Muscle; 2020 Jun; 10(1):18. PubMed ID: 32498713 [TBL] [Abstract][Full Text] [Related]
5. Vemurafenib improves muscle histopathology in a mouse model of LAMA2-related congenital muscular dystrophy. Oliveira-Santos A; Dagda M; Wittmann J; Smalley R; Burkin DJ Dis Model Mech; 2023 Jun; 16(6):. PubMed ID: 37021539 [TBL] [Abstract][Full Text] [Related]
6. Transgenic overexpression of the α7 integrin reduces muscle pathology and improves viability in the dy(W) mouse model of merosin-deficient congenital muscular dystrophy type 1A. Doe JA; Wuebbles RD; Allred ET; Rooney JE; Elorza M; Burkin DJ J Cell Sci; 2011 Jul; 124(Pt 13):2287-97. PubMed ID: 21652631 [TBL] [Abstract][Full Text] [Related]
7. Laminin-111 protein therapy after disease onset slows muscle disease in a mouse model of laminin-α2 related congenital muscular dystrophy. Barraza-Flores P; Bukovec KE; Dagda M; Conner BW; Oliveira-Santos A; Grange RW; Burkin DJ Hum Mol Genet; 2020 Aug; 29(13):2162-2170. PubMed ID: 32472139 [TBL] [Abstract][Full Text] [Related]
9. LAMA2-related myopathy: Frequency among congenital and limb-girdle muscular dystrophies. Løkken N; Born AP; Duno M; Vissing J Muscle Nerve; 2015 Oct; 52(4):547-53. PubMed ID: 25663498 [TBL] [Abstract][Full Text] [Related]
10. Absence of microRNA-21 does not reduce muscular dystrophy in mouse models of LAMA2-CMD. Moreira Soares Oliveira B; Durbeej M; Holmberg J PLoS One; 2017; 12(8):e0181950. PubMed ID: 28771630 [TBL] [Abstract][Full Text] [Related]
11. Laminin α1 reduces muscular dystrophy in dy Gawlik KI; Harandi VM; Cheong RY; Petersén Å; Durbeej M Matrix Biol; 2018 Sep; 70():36-49. PubMed ID: 29544677 [TBL] [Abstract][Full Text] [Related]
12. A splice site mutation in laminin-α2 results in a severe muscular dystrophy and growth abnormalities in zebrafish. Gupta VA; Kawahara G; Myers JA; Chen AT; Hall TE; Manzini MC; Currie PD; Zhou Y; Zon LI; Kunkel LM; Beggs AH PLoS One; 2012; 7(8):e43794. PubMed ID: 22952766 [TBL] [Abstract][Full Text] [Related]
13. Altered expression of the alpha7beta1 integrin in human and murine muscular dystrophies. Hodges BL; Hayashi YK; Nonaka I; Wang W; Arahata K; Kaufman SJ J Cell Sci; 1997 Nov; 110 ( Pt 22)():2873-81. PubMed ID: 9427295 [TBL] [Abstract][Full Text] [Related]
14. A Family of Laminin α2 Chain-Deficient Mouse Mutants: Advancing the Research on LAMA2-CMD. Gawlik KI; Durbeej M Front Mol Neurosci; 2020; 13():59. PubMed ID: 32457577 [TBL] [Abstract][Full Text] [Related]
15. Improving Reproducibility of Phenotypic Assessments in the DyW Mouse Model of Laminin-α2 Related Congenital Muscular Dystrophy. Willmann R; Gordish-Dressman H; Meinen S; Rüegg MA; Yu Q; Nagaraju K; Kumar A; Girgenrath M; Coffey CBM; Cruz V; Van Ry PM; Bogdanik L; Lutz C; Rutkowski A; Burkin DJ J Neuromuscul Dis; 2017; 4(2):115-126. PubMed ID: 28550268 [TBL] [Abstract][Full Text] [Related]
16. Zebrafish Models of Fabian L; Dowling JJ Front Mol Neurosci; 2020; 13():122. PubMed ID: 32742259 [TBL] [Abstract][Full Text] [Related]
17. Increased polyamines as protective disease modifiers in congenital muscular dystrophy. Kemaladewi DU; Benjamin JS; Hyatt E; Ivakine EA; Cohn RD Hum Mol Genet; 2018 Jun; 27(11):1905-1912. PubMed ID: 29566247 [TBL] [Abstract][Full Text] [Related]
19. Natural history, outcome measures and trial readiness in LAMA2-related muscular dystrophy and SELENON-related myopathy in children and adults: protocol of the LAST STRONG study. Bouman K; Groothuis JT; Doorduin J; van Alfen N; Udink Ten Cate FEA; van den Heuvel FMA; Nijveldt R; van Tilburg WCM; Buckens SCFM; Dittrich ATM; Draaisma JMT; Janssen MCH; Kamsteeg EJ; van Kleef ESB; Koene S; Smeitink JAM; Küsters B; van Tienen FHJ; Smeets HJM; van Engelen BGM; Erasmus CE; Voermans NC BMC Neurol; 2021 Aug; 21(1):313. PubMed ID: 34384384 [TBL] [Abstract][Full Text] [Related]
20. Cib2 binds integrin alpha7Bbeta1D and is reduced in laminin alpha2 chain-deficient muscular dystrophy. Häger M; Bigotti MG; Meszaros R; Carmignac V; Holmberg J; Allamand V; Akerlund M; Kalamajski S; Brancaccio A; Mayer U; Durbeej M J Biol Chem; 2008 Sep; 283(36):24760-9. PubMed ID: 18611855 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]